Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Supportive Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion Anaemia and Transfusion requirements.

Trial Profile

Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Supportive Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion Anaemia and Transfusion requirements.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms ABRAZA
  • Most Recent Events

    • 25 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 21 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top